KIF23在非小细胞肺癌中的表达及其预后作用：基于Oncomine数据挖掘的分析
[Expression of KIF23 and Its Prognostic Role in Non-small Cell Lung Cancer: Analysis Based on the Data-mining of Oncomine].
作者信息
Ye Liang, Li Huijuan, Zhang Fang, Lv Tangfeng, Liu Hongbing, Song Yong
机构信息
Department of Respiratory Medicine, Jinling Clinical Medical College of Nanjing Medical University, Nanjing 210006, China.
Department of Respiratory Medicine, Najing Hospital Affiliated to Nanjing Medical University (Nanjing First Hospital), Nanjing 210002, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2017 Dec 20;20(12):822-826. doi: 10.3779/j.issn.1009-3419.2017.12.05.
BACKGROUND
Non-small cell lung cancer (NSCLC) is one of the most common cause of cancer-related death worldwide. As the overall prognosis for affected patients is still poor, there is a need for biomarkers for prediction of survival and guiding individual therapy. This study is to explore the expression and significance of kinesin family member 23 (KIF23) in NSCLC.
METHODS
KIF23 data were retrieved from Oncomine NSCLC database. The prognostic value of KIF23 was retrieved from an online survival analysis tool "Kaplan-Meier Plotter" (KM plotter) database.
RESULTS
In Oncomine database, there were 447 studies of different types concerning expression of KIF23, of which 67 studies were of statistically significance (64 up-regulated and 3 down-regulated). A total of 16 studies were involved KIF23 in NSCLC tissues and normal tissues, including a total of 1,189 samples. Overall, KIF23 expression in NSCLC is higher than that in normal tissues (P<0.05). Moreover, Kaplan-Meier plots of overall survival indicated that KIF23 high expression is closely associated with poor survival in NSCLC (P<0.05). Subgroup analysis revealed that KIF23 expression showed negative relation to the prognosis of pulmonary adenocarcinoma patients. Whereas, in those with squamous carcinoma KIF23 expression showed no effects on the prognosis of the patients.
CONCLUSIONS
KIF23 was found highly expressed in NSCLC, which might be a marker for NSCLC prognosis.
背景
非小细胞肺癌（NSCLC）是全球癌症相关死亡的最常见原因之一。由于受影响患者的总体预后仍然很差，因此需要生物标志物来预测生存期并指导个体化治疗。本研究旨在探讨驱动蛋白家族成员23（KIF23）在NSCLC中的表达及意义。
方法
从Oncomine NSCLC数据库中检索KIF23数据。从在线生存分析工具“Kaplan-Meier Plotter”（KM plotter）数据库中检索KIF23的预后价值。
结果
在Oncomine数据库中，有447项关于KIF23表达的不同类型研究，其中67项具有统计学意义（64项上调，3项下调）。共有16项研究涉及NSCLC组织和正常组织中的KIF23，包括总共1189个样本。总体而言，NSCLC中KIF23的表达高于正常组织（P<0.05）。此外，总生存的Kaplan-Meier曲线表明，KIF23高表达与NSCLC患者的不良生存密切相关（P<0.05）。亚组分析显示，KIF23表达与肺腺癌患者的预后呈负相关。然而，在鳞状细胞癌患者中，KIF23表达对患者预后无影响。
结论
发现KIF23在NSCLC中高表达，这可能是NSCLC预后的一个标志物。
Zotero 插件